Back to Journals » Therapeutics and Clinical Risk Management » Volume 4 » Issue 1

Critical appraisal of medical devices in the management of cerebrovascular disease

Authors Michael J Schneck

Published 8 February 2008 Volume 2008:4(1) Pages 19—29

DOI https://doi.org/10.2147/TCRM.S106

Michael J Schneck

Departments of Neurology and Neurological Surgery, Loyola University Chicago, Stritch School of Medicine, Maywood, Illinois, USA

Abstract: Medical devices may revolutionize the management of acute ischemic stroke and prevention of recurrent events. By comparison with pharmaceuticals, the device approval process and subsequent application of these devices in stroke treatment is founded on a paucity of Class I evidence-based clinical trial data. Thromboembolectomy for acute stroke, stenting of cervical or cerebral arteries for stroke prevention, and percutaneous closure of patent foramen ovale for prevention or recurrent cerebral ischemia are being done with an ever-increasing frequency despite few, if any, randomized clinical trials to confirm the appropriateness of the interventions. The current basis, or lack thereof, for these interventions for cerebrovascular disease is therefore discussed. As such, a critical appraisal of the available clinical data does not support widespread use of medical devices at this time outside of well-designed clinical trials.

Keywords: medical devices, stroke, PFO closure, stents, clot retrieval devices, clinical trials

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Readers of this article also read:

A review of topotecan in combination chemotherapy for advanced cervical cancer

Minoo Robati, David Holtz, Charles J Dunton

Therapeutics and Clinical Risk Management 2008, 4:213-218

Published Date: 8 February 2008

Serotonin receptor modulators in the treatment of irritable bowel syndrome

Mohammad Fayyaz, Jeffrey M Lackner

Therapeutics and Clinical Risk Management 2008, 4:41-48

Published Date: 8 February 2008

Why does the world need another rotavirus vaccine?

Richard L Ward, Monica M McNeal, A Duncan Steele

Therapeutics and Clinical Risk Management 2008, 4:49-63

Published Date: 8 February 2008

Trabectedin and its potential in the treatment of soft tissue sarcoma

Philippe A Cassier, Armelle Dufresne, Jean-Yves Blay, Jérôme Fayette

Therapeutics and Clinical Risk Management 2008, 4:109-116

Published Date: 8 February 2008

Management of laryngopharyngeal reflux with proton pump inhibitors

Christina Reimer, Peter Bytzer

Therapeutics and Clinical Risk Management 2008, 4:225-233

Published Date: 8 February 2008

A review of telavancin in the treatment of complicated skin and skin structure infections (cSSSI)

Lala M Dunbar, Derek M Tang, Robert M Manausa

Therapeutics and Clinical Risk Management 2008, 4:235-244

Published Date: 8 February 2008

Zoledronic acid in the management of metastatic bone disease

Thomas J Polascik, Vladimir Mouraviev

Therapeutics and Clinical Risk Management 2008, 4:261-268

Published Date: 8 February 2008